Metabolon Launches Peak Science Grant Program to Accelerate Metabolomics-Driven Discovery
核心洞察
Metabolon, Inc. (搜索) announced the launch of the Peak Science Grant Program, a competitive quarterly grant providing researchers with no-cost access to its metabolomics platform and scientific expertise.
Each quarter, three finalists will be selected and one winning project will receive a fully funded metabolomics study covering up to 100 qualified samples, bioinformatics tools, and data interpretation support.
Applications are open to academic and industry researchers across disease biology, translational research, population health, microbiome research, and related disciplines, with the current quarter deadline set for September 30, 2026.
MORRISVILLE, N.C., August 11, 2026 — Metabolon, Inc. (搜索), the global leader in metabolomics solutions, today announced the launch of the Metabolon Peak Science Grant Program, a competitive quarterly grant initiative designed to provide researchers with no-cost access to the company's industry-leading metabolomics platform, analytical services, bioinformatics tools, and scientific expertise.
The program represents a strategic investment in accelerating transformative research by equipping investigators with high-quality metabolomics data and expert guidance. Each quarter, Metabolon will select three finalists and award one winning project a fully funded metabolomics study.
"Metabolomics has the power to reveal biology that other technologies can miss, providing a direct view into phenotype, function, and biochemical activity," said Rohan Hastie, CEO of Metabolon. "Through the Peak Science Grant Program, we are helping researchers bring metabolomics into promising studies that can advance discovery, strengthen scientific decision-making, and open new paths for understanding health, disease, and biological systems."
Grant Scope and Award Details
The winning project will receive a comprehensive Metabolon-supported metabolomics study at no cost. The award package includes consultation with Metabolon scientists on study design and statistical power, metabolomics analysis of up to 100 qualified samples, comprehensive project deliverables including a standard interpretation report and supporting datasets, access to the Metabolon Integrated Bioinformatics Platform for data analysis and visualization, and scientific guidance for biological interpretation and downstream data analysis.
Finalists will be invited to discuss their proposed projects with Metabolon's scientific and business development representatives to confirm feasibility, timelines, sample requirements, and other study details before the final grant award winner is selected. Finalists will also receive a 10% credit toward a future Metabolon project.
Eligibility and Evaluation Criteria
The program is open to researchers seeking to use metabolomics to uncover new biology, strengthen an existing study, support translational discovery, generate preliminary data for future funding, or inform scientific decision-making. Applications are encouraged from researchers in academia and industry working across disease biology, translational research, population health, microbiome research, nutrition, environmental health, and related life science disciplines.
Applications will be evaluated based on scientific impact, feasibility, and innovation. Reviewers will consider whether the proposed study has the potential to uncover new insights, advance biological understanding, improve scientific decision-making, and demonstrate a creative or novel use of metabolomics. All applications will be reviewed by a panel of senior scientific leaders from Metabolon's R&D, lab operations, and Discovery & Translational Sciences teams.
Timeline and Application Deadlines
The submission deadline for the current quarter is September 30, 2026, and for the fourth quarter, December 31, 2026. Applications will be reviewed promptly following each submission deadline.
Metabolomics: A Functional Readout of Biological Systems
Metabolomics, the large-scale study of all small molecules in a biological system, is the only omics technology that provides a complete current-state functional readout of a biological system. Unlike genomics or transcriptomics, metabolomics captures the combined impact of genetic and external factors — including drugs, diet, lifestyle, and the microbiome — on human health. By measuring thousands of discrete chemical signals that form biological pathways, metabolomics can reveal important biomarkers, enabling a better understanding of a drug's mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy.
Metabolon brings more than 25 years of experience, over 15,000 completed projects, more than 4,000 publications, and ISO 9001:2015, CLIA, and CAP certifications to the program. The company's Global Discovery Panel is powered by the world's largest proprietary metabolomics reference library.